[go: up one dir, main page]

GB201820157D0 - Method of treatment - Google Patents

Method of treatment

Info

Publication number
GB201820157D0
GB201820157D0 GBGB1820157.4A GB201820157A GB201820157D0 GB 201820157 D0 GB201820157 D0 GB 201820157D0 GB 201820157 A GB201820157 A GB 201820157A GB 201820157 D0 GB201820157 D0 GB 201820157D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1820157.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Imperial College of London
Original Assignee
Oxford University Innovation Ltd
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd, Imperial Innovations Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB1820157.4A priority Critical patent/GB201820157D0/en
Publication of GB201820157D0 publication Critical patent/GB201820157D0/en
Priority to PCT/GB2019/053514 priority patent/WO2020120965A1/en
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/10Cellular immunotherapy characterised by the cell type used
    • A61K40/11T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/30Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32T-cell receptors [TCR]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00Cellular immunotherapy
    • A61K40/40Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46Viral antigens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/7051T-cell receptor (TcR)-CD3 complex
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70535Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0636T lymphocytes
    • C12N5/0638Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1820157.4A 2018-12-11 2018-12-11 Method of treatment Ceased GB201820157D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1820157.4A GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment
PCT/GB2019/053514 WO2020120965A1 (en) 2018-12-11 2019-12-11 Modified cells for use in a method of treatment of disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1820157.4A GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment

Publications (1)

Publication Number Publication Date
GB201820157D0 true GB201820157D0 (en) 2019-01-23

Family

ID=65030170

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1820157.4A Ceased GB201820157D0 (en) 2018-12-11 2018-12-11 Method of treatment

Country Status (2)

Country Link
GB (1) GB201820157D0 (en)
WO (1) WO2020120965A1 (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103905A2 (en) * 2007-02-23 2008-08-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Antibodies that specifically bind irta and methods of use
WO2013006474A2 (en) * 2011-07-01 2013-01-10 Beckman Coulter, Inc. Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders
AU2015367317A1 (en) * 2014-12-17 2017-06-01 Cellectis Inhibitory chimeric antigen receptor (iCAR or N-CAR) expressing non-T cell transduction domain
GB201507119D0 (en) * 2015-04-27 2015-06-10 Ucl Business Plc Nucleic Acid Construct
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP3688155B1 (en) * 2017-09-28 2023-01-04 Immpact-Bio Ltd. A universal platform for preparing an inhibitory chimeric antigen receptor (icar)

Also Published As

Publication number Publication date
WO2020120965A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
ZA202006746B (en) Methods of treatment
GB201804514D0 (en) Treatment of pyroptosis
EP3684342C0 (en) Method of treatment
GB201714871D0 (en) Treatment method
SG11202104222TA (en) Method of treatment of biological surfaces
GB201815588D0 (en) Method of treatment
ZA201908539B (en) Method of treatment of cancer
GB201706406D0 (en) Method of treatment
GB201819924D0 (en) Treatment method
GB201804515D0 (en) Treatment of necroptosis
GB201717945D0 (en) Method for treatment of cancer
IL287250A (en) Method of treatment
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
SG11202105877YA (en) Method of treatment
GB201918853D0 (en) Methods of treatment
GB201602802D0 (en) Method of treatment
ZA202001536B (en) Method for the treatment of wastewaters
HUE049463T2 (en) Method for the treatment of ballast
IL290983A (en) Methods of treatment
GB201820236D0 (en) Method of treatment
GB201820157D0 (en) Method of treatment
GB201806569D0 (en) Method of treatment
GB201804021D0 (en) Method of treatment
GB201900942D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)
COOA Change in applicant's name or ownership of the application

Owner name: OXFORD UNIVERSITY INNOVATION LIMITED

Free format text: FORMER OWNERS: IP2IPO INNOVATIONS LIMITED;OXFORD UNIVERSITY INNOVATION LIMITED

Owner name: IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE

Free format text: FORMER OWNERS: IP2IPO INNOVATIONS LIMITED;OXFORD UNIVERSITY INNOVATION LIMITED